Opus Genetics Inc (IRD)

Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes

RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the...

Form 424B2 - Prospectus [Rule 424(b)(2)]

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Opus Genetics Highlights Five Gene Therapy Programs Targeting Significant Unmet Need in Patients with Inherited Retinal Diseases

Rapidly Advancing Five IRD Programs​ with Four Clinical Data Readouts Expected in 2027 RDH12, MERTK and RHO...

Form 8-K - Current report

Form S-3 - Registration statement under Securities Act of 1933

Opus Genetics to Host Virtual R&D Science Forum on Tuesday, June 16, 2026 Featuring Multiple Inherited Retinal Disease Experts

RESEARCH TRIANGLE PARK, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus...

Opus Genetics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., May 28, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a...

Opus Genetics to Present at the 2026 Jefferies Global Healthcare Conference

RESEARCH TRIANGLE PARK, N.C., May 27, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (“Opus...

Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form S-8 - Securities to be offered to employees in employee benefit plans